Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | TK2 | O00142 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL77830 | 0.99 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL176363 | 0.99 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL887722 | 0.99 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL21682515 | 0.99 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL8075845 | 0.99 | TK1 (0.67) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL29150139 | 0.97 | TK1 (0.65) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL7576317 | 0.95 | TK1 (0.66) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL5692278 | 0.95 | TK1 (0.66) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL9386574 | 0.95 | TK1 (0.66) | TK1LMNASMN1; SMN2POLBTK2 | |
| Doxribtimine SCHEMBL9385913 | 0.95 | TK1 (0.66) | TK1LMNASMN1; SMN2POLBTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0318464-B1 | ANTITUMOR PLATINUM COMPLEXES | Bristol-Myers Squibb Company (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0318464-A2 | Antitumor platinum complexes | Bristol-Myers Squibb Company (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0306605-A1 | Antitumor platinum complexes | Bristol-Myers Squibb Company (US) | 1989-03-15 | — | — | EP | disclosed |
| US-4594418-A | A 1,2-cyclohexane platinum complex | BRISTOL-MYERS COMPANY (US) | 1986-06-10 | — | — | US | disclosed |
| US-4562275-A | ANTICARCINOGENIC AGENTS | BRISTOL-MYERS CO. (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0155705-A2 | Antitumor platinum complexes | Bristol-Myers Squibb Company (US) | 1985-09-25 | — | — | EP | disclosed |